Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-FPI-1966 + Vofatamab |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-FPI-1966 | 225Ac-Vofatamab|[225Ac]-FPI-1966|actinium-225 vofatamab | 225Ac-FPI-1966 is a radioconjugate comprising vofatamab, a monoclonal antibody that targets FGFR3, linked to the radionuclide Actinium-225, which delivers radiation to tumor cells, potentially resulting in cytotoxic effects (NCI Drug Dictionary). | ||
| Vofatamab | B-701|MFGR1877S|RG-7444|R3Mab | FGFR3 Antibody 5 | Vofatamab (B-701) is a monoclonal antibody, which binds FGFR3 to prevent phosphorylation and signaling, thereby inhibiting proliferation and promoting apoptosis in cancer cells (Journal of Clinical Oncology 36, no. 15_suppl (May 20 2018) 4534-4534, PMID: 22203368). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05363605 | Phase Ib/II | 225Ac-FPI-1966 + Vofatamab | A Study of [225Ac]-FPI-1966 in Participants With Advanced Solid Tumours | Terminated | USA | AUS | 0 |